(Myovant) Shares of Myovant Sciences fell more than 19% on Tuesday after the US Food and Drug Administration cited deficiencies in filing for an endometriosis drug.
FDA did not offer additional details of the declined application. The regulator said that the notice does not reflect its final decision, with the application going for further review.
The investigational drug, MYFEMBREE®, was being developed in collaboration with Pfizer. The companies said that they will continue working with the FDA for the next steps of the application.
The experimental drug was meant for the management of moderate to severe pain caused by endometriosis.
MYOV: NYSE is down -19.25%, PFE: NYSE is down -0.56%.
